• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Shark Bites: A Computational Predictive Biology Play

Upcoming catalyst are likely to put the stock on the radar screen of investors.
By JAMES "REV SHARK" DEPORRE
Jan 13, 2021 | 02:36 PM EST
Stocks quotes in this article: EVGN, ARKG

Evogene Ltd.  (EVGN) is a small Israeli company that is using something called computational predictive biology to develop products in four different areas.

Computation Predictive Biology (CPB) is defined as "the development and application of data-analytical and theoretical methods, mathematical modeling and computational simulation techniques to the study of biological, ecological, behavioral, and social systems." More details can be found on Wikipedia.

EVGN believes that its CPB platform gives it a competitive edge that increases efficacy, reduces toxicity, cuts costs of development, and saves time. Forty of EVGN's 121 employees hold Ph.D.'s in a variety of disciplines.

EVGN has four subsidiaries, each with a different focus. The key areas of development are microbiome therapeutics, herbicides, pesticides, and medical cannabis.

This is obviously a highly complex business, but it is still quite small, and there are some upcoming catalysts that are likely to put the stock on the radar screen of investors.

One investor that already has discovered this stock is the Ark Genomic Revolution ETF (ARKG) , which was one of the top-performing ETFs in 2020. ARK is the largest investor in EVGN, and as of Jan. 12, 2021, held 4,583,323 shares of the 31.6 million that are outstanding.

The EVGN chart looks favorable as it consolidates in the $4.75-$5 area. I am looking to build this position further on any pullbacks.

Please note that due to factors including low market capitalization and/or insufficient public float, we consider EVGN to be a small-cap stock. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Rev Shark was long EVGN.

TAGS: Investing | Small Cap | Stocks | Trading | Biotechnology | Middle East

More from Stocks

Beyond Meat and Peloton: Zombie Stocks Can Turn Portfolios Into the Walking Dead

Brad Ginesin
May 30, 2023 3:30 PM EDT

Don't confuse a stock revival masquerading as a living, breathing business revival.

In Case You Missed It: Apple Just Hit a New 52-Week High

Bruce Kamich
May 30, 2023 2:45 PM EDT

Let's not ignore the strength in AAPL.

Bristol-Myers Squibb Breaks a Key Support Area: What's Next?

Bruce Kamich
May 30, 2023 12:50 PM EDT

Here's what the charts and indicators say.

Here's the Truth About Oil No One Saw, as OPEC+ Takes the Stage

Maleeha Bengali
May 30, 2023 12:32 PM EDT

Let's look at what many observers failed to notice about oil, and what could happen when the oil exporting nations -- including Russia -- meet on June 4.

C3.ai Is My Lottery Ticket: Here's How Traders Can Cash In

Stephen Guilfoyle
May 30, 2023 11:50 AM EDT

The firm, which considers itself an enterprise AI software company, reports earnings after Wednesday's close

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:48 AM EDT CHRIS VERSACE

    Latest AAP Podcast With Portillo's CEO!

    Listen in as we talk with a rising star in the Chi...
  • 03:25 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Don't Just Sit There and 'Hope' for Your Stocks, M...
  • 07:32 AM EDT BOB LANG

    Webinar Thursday After the Close: Option Spread Trading

    Thursday, my good friend and colleague Sam DeMarco...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login